Ulta Beauty’s CEO reveals how the GLP-1 weight-loss drug boom is fueling unexpected demand for hair loss treatments and anti-sagging skincare, turning side effects into a retail windfall amid economic pressures on American families.
Story Highlights
- Ulta CEO Kecia Steelman confirms GLP-1 drugs like Ozempic and Wegovy drive sales of haircare and skincare products addressing rapid weight loss side effects.
- Hair loss affects 3% of Wegovy trial users; “Ozempic face” sagging prompts moisture and elasticity solutions, overlapping with aging skin needs.
- Ulta posted $12.39 billion in 2025 sales, up 11.8%, with skincare, hair, and wellness comprising 43% of revenue; stock rose 50% in the past year.
- By 2025, about 10% of Americans used weight-loss drugs, boosting “recession-resistant” beauty self-care amid frustrations with high costs and inflation.
- Skincare brands launch targeted products like VOL.U.LIFT serum, signaling pharma-beauty industry pivot without government oversight.
Steelman Spotlights GLP-1 Side Effects
Kecia Steelman, Ulta Beauty’s CEO, stated in a Yahoo Finance interview released April 6, 2026, that GLP-1 drugs like Ozempic and Wegovy create real demand for specific haircare and skincare. She highlighted hair loss as a documented issue, with 3% of Wegovy trial participants affected. Rapid weight reduction also causes skin elasticity loss and moisture deficits, dubbed “Ozempic face.” These needs mirror aging skin concerns, driving customers to products that promote skin longevity. Ulta positions itself to meet this surge through its 46.7 million loyalty members.
Ulta’s Sales Surge Amid Broader Trends
Ulta Beauty reported $12.39 billion in 2025 sales, a 11.8% increase from prior year, with skincare, haircare, and wellness accounting for 43% of revenue. The company’s stock climbed 50% over the past year, reflecting robust consumer spending on self-care despite economic headwinds like inflation and high energy costs. GLP-1 adoption reached about 10% of the U.S. population by 2025, per EY estimates, intersecting with beauty retail’s recession-resistant nature. Steelman noted significant uptick in related categories without naming top products.
Industry Responds with Targeted Innovations
Skincare brands adapt to GLP-1 users’ challenges, including the “4 D’s”: deflation, density loss, wrinkles, and dehydration. Image Skincare’s VOL.U.LIFT serum features antioxidants, L-ornithine, bakuchiol, and hyaluronic acid to restore volume. SkinCeuticals’ A.G.E. Interrupter targets glycation and collagen loss, while Skinbetter Science’s InterFuse cream provides peptides and hydration. Galderma earlier reported filler demand for sagging skin via its SCULPT & LIFT protocol. Experts like Dr. Marc Ronert affirm clinical improvements in firmness.
Expert Views and Market Optimism
Experts offer balanced perspectives on GLP-1 skincare demand. Dr. Engelman states products are not exclusive to drug users but use beneficial ingredients. Dr. Yang sees early-stage trends shifting toward metabolic science formulas. Chemist Ursula Diaz praises VOL.U.LIFT’s ingredient mix, noting L-ornithine’s emergence. SkinCeuticals’ Marrone aligns products with drug-induced laxity. Steelman’s comments fuel optimism, with Ulta declining specifics on bestsellers. This pharma-beauty crossover grows as Americans prioritize personal health over elite-driven policies.
Conservatives and liberals alike voice frustrations with government overspending and elite priorities that inflate costs, making self-reliant solutions like affordable beauty retail vital. Ulta’s gains underscore free-market adaptation to consumer needs, free from federal overreach, as families combat side effects of popular drugs without new mandates.
Sources:
Ulta’s CEO Said GLP-1 Craze Has Created Demand for Certain Haircare and Skincare Products
The new skincare designed for GLP-1 users—and what dermatologists want you to know
